1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:30 2022-08-18 am EDT
93.10 CHF   -1.17%
07/29TRANSCRIPT : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
07/29Medacta Expects to Hit Top End of FY Revenue Guidance After 19% Growth in H1
MT
07/29MEDACTA : 2022 Half-Year Unaudited Top-Line Figures Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medacta : Announces First Lumbar Fusion Procedure with NextAR Spine Augmented Reality Surgical Application in US Read More >

04/25/2022 | 01:10pm EDT


Media Release

Medacta Announces First Lumbar Fusion Procedure with NextAR Spine Augmented Reality Surgical Application in US

CASTEL SAN PIETRO, Switzerland, 25 April 2022 - Medacta announces the successful completion of the first lumbar fusion procedure in the United States utilizing the M.U.S.T.(R) Pedicle Screw System in combination with the NextAR(TM) Spine, the first CE-marked and FDA-cleared Augmented Reality (AR)-based surgical application with intraoperative guidance in spine surgery. The procedure was performed by Kevin J. McGuire, M.D., M.S., Section Chief of Orthopaedic Spine Surgery at the Center for Pain and Spine at Dartmouth-Hitchcock Medical Center (DHMC) in Lebanon, New Hampshire.

'While utilizing the 3D Direct option, I was able to seamlessly register the NextAR Platform to my intraoperative 3D scan, accurately place the pedicle screws, and enjoy the ability to keep my eyes on my patient the entire time using the NextAR Smart Glasses. Implementing the NextAR Platform didn't compromise any of my current workflow and actually, worked better than I anticipated' says Kevin J. McGuire, M.D., M.S.

The NextAR Spine Application assists the surgeon in precisely locating the anatomical structures in either open, mini-open or percutaneous spine procedures for the safe placement of spine implants. The system tracks the patient's anatomy, continuously updating its position on patient-specific 3D x-ray images, such as 3D C-Arm or 3D CT scan. The surgeon can accurately plan and execute spine surgeries by selecting among real-time (3D Direct) and preoperative planning (3D-3D) approaches.

During the operation, NextAR empowers the surgeon's vision with unique real-time surgical guidance superimposed onto the operative field to enhance precision and enable data-driven decision-making. This enables personalized adjustments based on each patient's unique anatomy and biomechanics.

NextAR is Medacta's proprietary Augmented Reality Surgical Platform, which includes dedicated smart delivery tools:

- NextAR TS, Tracking System, a compact, integrated single-use solution, delivered terminally sterile.

- NextAR Smart Glasses, surgical guidance on the surgeon's line-of-sight.

NextAR is the first platform to offer personalized augmented reality solutions for both joint replacement and spine procedures. In line with Medacta's philosophy of healthcare sustainability, the NextAR platform is offered as a hardware system with limited capital investment and single-use instrumentation at a low cost per-case and offers the ability to host software for multiple applications. The platform represents an optimal solution worldwide and particularly for U.S. Ambulatory Surgery Centers (ASCs).

The NextAR surgical platform is part of Medacta's MySolutions Personalized Ecosystem, an advanced network of digital solutions designed to improve patient outcomes and healthcare efficiency. MySolutions embodies Medacta's holistic approach to personalized medicine, aiming to bring value to every step of the patient journey from preoperative through postoperative care.

With Medacta, the surgeon is never alone while discovering new technologies. These latest advancements are supported by personalized high-level educational pathways designed by the M.O.R.E. Institute, which can rely on the collaboration of an international network of expert surgeons.

For more information about the NextAR Platform, please visit nextar.medacta.com.

Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60

media@medacta.ch

About Medacta
Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with expert surgeons globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

Disclaimer

Medacta Group SA published this content on 25 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 April 2022 17:09:08 UTC.


© Publicnow 2022
All news about MEDACTA GROUP SA
07/29TRANSCRIPT : Medacta Group SA, H1 2022 Earnings Call, Jul 29, 2022
CI
07/29Medacta Expects to Hit Top End of FY Revenue Guidance After 19% Growth in H1
MT
07/29MEDACTA : 2022 Half-Year Unaudited Top-Line Figures Presentation
PU
07/29Medacta Group SA reports 19.0% growth of half-year revenue
EQ
07/29Medacta Group SA Announces Unaudited Revenue Results for the First Half Ended June 30, ..
CI
07/29Medacta Group SA Provides Revenue Guidance for the Year 2022
CI
06/23Medacta Announces First Lumbar Fusion Procedure with NextAR Augmented Reality Surgical ..
EQ
05/24MEDACTA : Company Presentation
PU
05/19Medacta Group announces the results of today's Annual General Meeting
EQ
05/19Medacta Group SA Approves Distribution
CI
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 427 M 433 M 433 M
Net income 2022 57,0 M 57,8 M 57,8 M
Net Debt 2022 115 M 116 M 116 M
P/E ratio 2022 32,0x
Yield 2022 0,66%
Capitalization 1 927 M 1 953 M 1 953 M
EV / Sales 2022 4,78x
EV / Sales 2023 4,17x
Nbr of Employees 1 341
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 96,38 €
Average target price 115,60 €
Spread / Average Target 19,9%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-34.44%1 953
ABBOTT LABORATORIES-21.87%193 597
MEDTRONIC PLC-7.94%126 108
BECTON, DICKINSON AND COMPANY7.30%75 357
HOYA CORPORATION-11.46%39 823
SARTORIUS STEDIM BIOTECH-17.54%37 347